Gilead Sciences, Inc. is expected to report earnings after market close. According to Zacks Investment Research, based on 7 analysts' forecasts, the consensus EPS forecast for the quarter is $1.53. The reported EPS for the same quarter last year was $1.37.
Gilead under performed the XBI - S&P Biotech ETF since Q3 2016. Horizontal support at $60.32 will be a key technical level to watch out for.
Gilead under performed the XBI - S&P Biotech ETF since Q3 2016. Horizontal support at $60.32 will be a key technical level to watch out for.